CryoPort, Inc. (NASDAQ:CYRX - Get Free Report) CEO Jerrell Shelton sold 69,135 shares of CryoPort stock in a transaction that occurred on Friday, June 20th. The stock was sold at an average price of $6.47, for a total value of $447,303.45. Following the transaction, the chief executive officer now owns 912,419 shares of the company's stock, valued at $5,903,350.93. This represents a 7.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Jerrell Shelton also recently made the following trade(s):
- On Tuesday, June 17th, Jerrell Shelton sold 151,304 shares of CryoPort stock. The shares were sold at an average price of $6.81, for a total value of $1,030,380.24.
- On Wednesday, June 18th, Jerrell Shelton sold 119,281 shares of CryoPort stock. The shares were sold at an average price of $6.81, for a total transaction of $812,303.61.
- On Monday, March 24th, Jerrell Shelton sold 2,980 shares of CryoPort stock. The shares were sold at an average price of $6.94, for a total transaction of $20,681.20.
CryoPort Price Performance
Shares of NASDAQ CYRX traded up $0.19 during mid-day trading on Monday, reaching $6.56. The company had a trading volume of 572,912 shares, compared to its average volume of 529,975. The firm has a market cap of $328.92 million, a price-to-earnings ratio of -2.80 and a beta of 1.85. The business's 50-day simple moving average is $6.20 and its 200 day simple moving average is $6.70. CryoPort, Inc. has a one year low of $4.58 and a one year high of $9.78. The company has a debt-to-equity ratio of 0.51, a quick ratio of 5.24 and a current ratio of 5.56.
CryoPort (NASDAQ:CYRX - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported ($0.22) EPS for the quarter, beating the consensus estimate of ($0.23) by $0.01. CryoPort had a negative net margin of 50.15% and a negative return on equity of 11.03%. The company had revenue of $41.04 million during the quarter, compared to analysts' expectations of $56.19 million. On average, research analysts predict that CryoPort, Inc. will post -0.99 earnings per share for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asia Singapore Pte. Ltd. boosted its stake in shares of CryoPort by 148.7% in the 4th quarter. Point72 Asia Singapore Pte. Ltd. now owns 3,546 shares of the company's stock valued at $28,000 after purchasing an additional 2,120 shares in the last quarter. Lazard Asset Management LLC bought a new position in CryoPort in the 4th quarter valued at approximately $51,000. SBI Securities Co. Ltd. boosted its position in CryoPort by 548,750.0% in the first quarter. SBI Securities Co. Ltd. now owns 10,977 shares of the company's stock valued at $67,000 after buying an additional 10,975 shares in the last quarter. Quarry LP bought a new stake in shares of CryoPort during the fourth quarter worth $69,000. Finally, CWM LLC increased its holdings in shares of CryoPort by 1,437.0% during the first quarter. CWM LLC now owns 11,328 shares of the company's stock worth $69,000 after buying an additional 10,591 shares in the last quarter. Institutional investors own 92.90% of the company's stock.
Analyst Ratings Changes
A number of brokerages have recently issued reports on CYRX. Needham & Company LLC restated a "buy" rating and set a $11.00 price objective on shares of CryoPort in a report on Thursday, May 8th. Morgan Stanley reduced their price target on CryoPort from $8.00 to $7.00 and set an "equal weight" rating for the company in a research note on Monday, May 5th. Guggenheim reaffirmed a "buy" rating and issued a $10.00 price objective on shares of CryoPort in a report on Wednesday, April 16th. UBS Group lifted their target price on CryoPort from $10.00 to $11.00 and gave the stock a "buy" rating in a report on Tuesday, April 1st. Finally, Roth Mkm reissued a "buy" rating and issued a $15.00 price objective on shares of CryoPort in a report on Tuesday, April 1st. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $11.00.
Get Our Latest Stock Analysis on CYRX
About CryoPort
(
Get Free Report)
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
Featured Stories
Before you consider CryoPort, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CryoPort wasn't on the list.
While CryoPort currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
